Klaviyo, Inc. director Roxanne Oulman filed a Form 4 on November 9, 2026, disclosing a sale of 13,989 shares of Series A Common Stock on November 6, 2026, alongside a trust transfer of 12,881 shares, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Sale transaction: Oulman disposed of 13,989 shares of Series A Common Stock on November 6, 2026, at a weighted average price of $20.36 per share, with individual transaction prices ranging from $20.32 to $20.40.
  • 10b5-1 plan: According to the filing, the sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2026.
  • Trust transfer: 12,881 shares were transferred from the Roxanne Oulman 2025 GRAT to The Grant Oulman and Roxanne Oulman Revocable Living Trust under the exemption afforded by Rule 16a-13.
  • Post-transaction ownership: Following the reported transactions, Oulman beneficially owns 23,354 securities in total, consisting of 8,532 shares of Series A Common Stock held directly and 14,822 unvested restricted stock units under the issuer's 2023 Stock Option and Incentive Plan.
  • Relationship to issuer: The filing identifies Oulman as a director of Klaviyo, Inc., traded on NASDAQ:KVYO.

Oulman's November 6 Share Sale and Trust Transfer at Klaviyo

According to the Form 4 filed with the SEC on November 9, 2026, Roxanne Oulman, a director of Klaviyo, Inc. (NASDAQ:KVYO), sold 13,989 shares of the company's Series A Common Stock on November 6, 2026. The filing states that the shares were sold in multiple transactions at prices ranging from $20.32 to $20.40 per share, with a weighted average price of $20.36. The filing notes that Oulman undertakes to provide full information regarding the number of shares sold at each separate price upon request.

The filing also discloses a transfer of 12,881 shares of Series A Common Stock from the Roxanne Oulman 2025 GRAT to The Grant Oulman and Roxanne Oulman Revocable Living Trust, of which Oulman serves as co-trustee. The filing states this transfer was made in accordance with the exemption afforded by Rule 16a-13 of the Securities Exchange Act of 1934. Following the transfer, 12,881 shares are held by the revocable living trust and 3,894 shares remain held by the Roxanne Oulman 2025 GRAT, for which Oulman serves as trustee. The filing notes that Oulman disclaims Section 16 beneficial ownership of shares held in both the trust and the GRAT, except to the extent of her pecuniary interest therein.

After all reported transactions, the filing states that Oulman's total beneficial ownership stands at 23,354 securities, comprised of 8,532 shares of Series A Common Stock held directly and 14,822 unvested restricted stock units awarded under the issuer's 2023 Stock Option and Incentive Plan, each representing the contingent right to receive one share of Series A Common Stock upon vesting and settlement. The filing was signed by Landon Edmond as Attorney-in-Fact on November 9, 2026.

What Was Disclosed

Klaviyo director Roxanne Oulman disclosed a sale of 13,989 shares of Series A Common Stock at a weighted average of $20.36 on November 6, 2026, executed under a 10b5-1 plan, plus a Rule 16a-13 trust transfer of 12,881 shares, leaving her with 23,354 total beneficial securities.